(Q52836247)

8 May 2018

title

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

8 May 2018

0 references

1 reference

4

1 reference

8 May 2018

ESMO Guidelines Committee

8

object named as

ESMO Guidelines Committee

1 reference

8 May 2018

Tadeusz Robak

2

object named as

T Robak

1 reference

8 May 2018

author name string

B Eichhorst

1

1 reference

8 May 2018

E Montserrat

3

1 reference

8 May 2018

P Hillmen

5

1 reference

8 May 2018

M Hallek

6

1 reference

8 May 2018

C Buske

7

1 reference

8 May 2018

publication date

1 September 2015

1 reference

8 May 2018

published in

Annals of Oncology

1 reference

8 May 2018

volume

26 Suppl 5

1 reference

8 May 2018

page(s)

v78-84

1 reference

8 May 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV303

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV303

1 reference

8 May 2018

release_64bod5dlxfekdoxwxwy2bfnfja

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/64bod5dlxfekdoxwxwy2bfnfja

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

8 May 2018